Cargando…

BRCA2 interacting proteins

Detalles Bibliográficos
Autores principales:	Vidarsson, H, Mikaelsdottir, E, Eyfjörd, JE, Ögmundsdóttir, H, Rafnar, T, Valgeirsdóttir, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2000
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3300858/ http://dx.doi.org/10.1186/bcr160

Ejemplares similares

The Icelandic founder mutation BRCA2 999del5: analysis of expression
por: Mikaelsdottir, Evgenia K, et al.
Publicado: (2004)

Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells
por: Ragnarsson, G B, et al.
Publicado: (2000)

The GSTT1 genotype is associated with p53 mutation status of breast cancer tumours
por: Gudmundsdóttir, K, et al.
Publicado: (2000)

Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes
por: Stefansson, Olafur Andri, et al.
Publicado: (2009)

Haplotype analysis in German families with recurrent BRCA1 and BRCA2 mutations
por: Wappenschmidt, B, et al.
Publicado: (2001)

Correction: Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes
por: Stefansson, Olafur Andri, et al.
Publicado: (2009)

Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
por: Phillips, KA, et al.
Publicado: (2012)

Breast cancer in young women: prevalence of LOH at p53, BRCA1 and BRCA2
por: Johnson, SM, et al.
Publicado: (2000)

Mutational analysis of BRCA1 and BRCA2 genes in Spanish women with early-onset breast cancer
por: Martínez-Ferrandis, JI, et al.
Publicado: (2000)

Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland
por: Bielecka, Helena, et al.
Publicado: (2012)

Estrogen receptor transcription and transactivation: Genetic modifiers of cancer risks conferred by BRCA1 and BRCA2
por: Devilee, P
Publicado: (2001)

Large genomic rearrangements in BRCA1 and BRCA2 genes in breast and ovarian cancer families in Poland
por: Bielecka, Helena, et al.
Publicado: (2012)

Genomic and phenotypic analysis of BRCA2 mutated breast cancers reveals co-occurring changes linked to progression
por: Stefansson, Olafur A, et al.
Publicado: (2011)

A multi-center study to evaluate the impact of germline BRCA1 and BRCA2 mutations on ovarian cancer survival
por: Bolton, KL, et al.
Publicado: (2012)

Germline mutations of BRCA1-associated RING domain (BARD1) gene in breast and/or ovarian families negative for BRCA1 and 2 alterations
por: Ghimenti, C, et al.
Publicado: (2000)

When, how and why BRCA1 and BRCA2 genetic testing is offered to patients who do not meet standard criteria
por: Duffy, J, et al.
Publicado: (2012)

BRCA1 testing in Lithuania
por: Janavicius, Ramunas
Publicado: (2012)

Constitutional alterations of 9p23-24 in independent BRCA2 breast cancer families
por: Schwab, M, et al.
Publicado: (2000)

BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial
por: Kote-Jarai, Z, et al.
Publicado: (2000)

Molecular characterization of BRCA1 and BRCA2 genes in breast cancer patients under 40 years-old or with familiar cancer history
por: Millan, Silvia Vidal, et al.
Publicado: (2007)

The contribution of LARGE genomic rearrangements of BRCA1 and BRCA2 gene mutations in breast and ovarian cancer families in a clinical cohort
por: Sawyer, S, et al.
Publicado: (2012)

Germline BRCA2 and somatic P53 alterations in male breast cancer
por: Csokay, B, et al.
Publicado: (2000)

Selenium and the risk of cancer in BRCA1 carriers
por: Lubinski, J, et al.
Publicado: (2011)

One test to identify 50% of all Norwegian BRCA1 mutations
por: Møller, P, et al.
Publicado: (2000)

Searching for BRCA3 by exome sequencing
por: Makunin, I, et al.
Publicado: (2012)

RAD21 overexpression is frequently observed in BRCA-X Prostate Cancers
por: Deb, S, et al.
Publicado: (2012)

Impact of BRCA1 mutation on survival after early onset breast cancer
por: Huzarski, T, et al.
Publicado: (2012)

Mammary-specific targeting of the murine BRCA2 breast cancer susceptibility gene in mice
por: Collins, NK, et al.
Publicado: (2000)

Expression profiling of BRCA1 associated breast tumors
por: Berns, EMJJ, et al.
Publicado: (2000)

What are the unmet support needs of women with a known BRCA1/2 mutation?
por: White, V, et al.
Publicado: (2012)

Constitutional genomic instability of 9p23-24 in BRCA2 mutation carriers
por: Savelyeva, L, et al.
Publicado: (2001)

Folic acid and cancer risk in BRCA1 carriers
por: Durda, Katarzyna, et al.
Publicado: (2012)

Cisplatin in breast cancer treatment in BRCA1 carriers
por: Gronwald, Jacek, et al.
Publicado: (2012)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

P53 mutations in breast and ovarian carcinomas from BRCA1 and 2 mutation carriers and noncarriers
por: Sensi, E, et al.
Publicado: (2000)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
por: Byrski, T, et al.
Publicado: (2012)

BRCA1 mutation analysis in breast and ovarian cancer families from Greece
por: Konstantopoulou, I, et al.
Publicado: (2000)

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

An audit of treatment focussed BRCA1/2 mutation testing at an integrated Familial Cancer Clinic
por: Lewis, A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_u3ah4jce4d33u3atbi5h4gqub7